Journal: Cancer Science

Article Title: Single‐Cell Transcription Reveals the Fibroblast Heterogeneity and Neural Cells' Significance in Desmoid Fibromatosis

doi: 10.1111/cas.70160

Figure Lengend Snippet: Identification of specific marker and transcription factor for desmoid fibromatosis (DF). (A) The overlapping genes among the upregulated genes in fibroblasts, DF‐derived fibroblasts, and mesenchymal fibroblasts. (B) Dotplot illustrating the scaled expressions of the overlapping genes in the four subtypes of fibroblasts and other cell types. (C) Violin plot showing the expression of ADAM12 in all cell types. (D) Violin plot displaying the expression of ADAM12 in the four subtypes of fibroblasts. (E) Violin plot illustrating the expression of ADAM12 in the three groups of fibroblasts. (F) The transcription activity of CREB3L1 in the four subtypes of fibroblasts. (G) Violin plot visualizing the expression of CREB3L1 in all cell types. (H) The correlation analysis between CREB3L1 and ADAM12 in fibroblasts. (I) Immunohistochemistry (IHC) of ADAM12 and CREB3L1 in DF and NF. (J) Statistical analysis of ADAM12 and CREB3L1 IHC expressions in 22 DF and 42 NF patients. (K) Correlations analysis of CREB3L1 and ADAM12 expressions in all patients (22 DF and 42 NF patients). (L) Immunofluorescence of fibroblast common (ADAM12, CREB3L1) and subtype markers (LAMP5, SULF1, SFRP4, THBS4) in DF.

Article Snippet: Nonspecific binding was blocked with 5% BSA prior to overnight incubation at 4°C with the following primary antibodies: LAMP5 (Invitrogen, PA5‐52112), SULF1 (Abcam, ab32763), SFRP4 (Abcam, ab154167), THBS4 (Invitrogen, PA5‐40501), ADAM12 (Proteintech, 14139‐1‐AP), CREB3L1 (Proteintech, 11235‐2‐AP), S100B (Abcam, ab52642), COL11A1 (Proteintech, 21841‐1‐AP), and MKI67 (Abcam, ab16667).

Techniques: Marker, Derivative Assay, Expressing, Activity Assay, Immunohistochemistry, Immunofluorescence

Journal: Scientific Reports

Article Title: Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma

doi: 10.1038/s41598-025-90121-0

Figure Lengend Snippet: Pan-cancer analysis of ADAM12 expression. ( A ) ADAM12 expression levels across various cancer types, including both tumor and normal tissues, based on data from TCGA and GTEx datasets. ( B ) ADAM12 expression in tumor cell lines from the CCLE dataset. ( C ) Expression of ADAM12 in diverse cancer cell lines as derived from the HPA dataset. ( D ) ADAM12 expression in brain cancer cell lines from the HPA dataset. ( E ) Cellular localization of ADAM12 as observed in the HPA database (*p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).

Article Snippet: In line with these findings, data from the Human Protein Atlas (HPA) also confirmed elevated ADAM12 expression in brain and kidney cancers (Fig. C).

Techniques: Expressing, Derivative Assay

Journal: Scientific Reports

Article Title: Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma

doi: 10.1038/s41598-025-90121-0

Figure Lengend Snippet: The expression levels of ADAM12 in various tumors. ( A ) ADAM12 gene expression in Breast invasive carcinoma (BRCA), Glioblastoma-Lower Grade Glioma(GBMLGG), Bladder Cancer (BLCA), Esophageal Carcinoma (ESCA), Kidney Chromophobe (KICH),Kidney Clear Cell Carcinoma (KIRC), Kidney Papillary Cell Carcinoma (KIRP), Ovarian Cancer (OV), Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Adrenocortical Cancer (ACC) using GEPIA2. ( B – L ) The correlation between ADAM12 expression and different cancer stages/histological grades of tumors. ( B ) GBMLGG, ( C ) GBM, ( D ) BRCA, ( E ) KIRC, ( F ) KIRP, ( G ) KICH, ( H ) BLCA, ( I ) LIAD, ( J ) LIHC, ( K ) ACC, ( L ) OV.

Article Snippet: In line with these findings, data from the Human Protein Atlas (HPA) also confirmed elevated ADAM12 expression in brain and kidney cancers (Fig. C).

Techniques: Expressing, Gene Expression

Journal: Scientific Reports

Article Title: Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma

doi: 10.1038/s41598-025-90121-0

Figure Lengend Snippet: Survival analysis of ADAM12 across pan-cancer from TCGA database. ( A ) Survival map depicting ADAM12 gene expression across pan-cancer types. ( B ) Forest plots illustrating the correlations between OS/DSS and ADAM12 expression across 38 cancer types. ( C ) ADAM12 expression, survival time, and status in the TCGA-GBMLGG dataset. Kaplan–Meier survival estimates for patients at all grades, along with ROC curves and AUC values for ADAM12 at 1-, 3-, and 5- years in the TCGA-GBMLGG dataset. ( D ) Kaplan–Meier analyses of the association between ADAM12 expression and OS in GBMLGG, Pan-kidney cohort KIPAN (KICH + KIRC + KIRP), LIHC, BRCA, KIRC, UVM, OV, MESO, KIRP, ACC and LUAD. ( E ) P-values, risk coefficients (HR), and confidence intervals were analyzed through univariate and multivariate Cox regression. A nomogram predicting 1-, 2- and 3-years overall survival of glioma patients. Calibration curves for the overall survival nomogram model in the discovery group. The dashed diagonal line represents the ideal model, while the blue, red, and orange lines represent the observed nomogram at 1-, 2-, and 3- years, respectively.

Article Snippet: In line with these findings, data from the Human Protein Atlas (HPA) also confirmed elevated ADAM12 expression in brain and kidney cancers (Fig. C).

Techniques: Gene Expression, Expressing

Journal: Scientific Reports

Article Title: Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma

doi: 10.1038/s41598-025-90121-0

Figure Lengend Snippet: Association between ADAM12 mRNA expression and clinicopathologic/prognostic data in TCGA-GBMLGG, CGGA, and GSE16011. The clinicopathologic features analyzed include WHO Grades ( A ), Histology ( B ), IHD_status ( C ), 1p/19q_status ( D ), and overall survival analysis of patients with high-and low-expression levels of ADAM12 and time-dependent ROC curves for OS ( E ). * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: In line with these findings, data from the Human Protein Atlas (HPA) also confirmed elevated ADAM12 expression in brain and kidney cancers (Fig. C).

Techniques: Expressing

Journal: Scientific Reports

Article Title: Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma

doi: 10.1038/s41598-025-90121-0

Figure Lengend Snippet: Correlation between ADAM12 expression and MATH, TMB, and MSI in various cancer types. Spearman correlation analysis of ADAM12 expression with MATH ( A ), MSI ( B ), and TMB ( C ) in the TCGA datasets. The horizontal axis represents the correlation coefficient, while the vertical axis represents different tumor types. The size of the dots reflects the magnitude of the correlation coefficient, and colors indicate the significance of the p-value. The deeper the blue, the smaller the p-value. ( D ) Correlation analysis between ADAM12 gene expression and MATH in TCGA-GBMLGG/LGG/GBM. ( E ) Correlation analysis between ADAM12 gene expression and MSI in TCGA-GBMLGG/LGG/GBM. ( F ) Correlation analysis between ADAM12 gene expression and TMB in TCGA-GBMLGG/LGG/GBM. The abscissa represents gene expression distribution, and the ordinate represents MATH/TMB/MSI score distribution. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: In line with these findings, data from the Human Protein Atlas (HPA) also confirmed elevated ADAM12 expression in brain and kidney cancers (Fig. C).

Techniques: Expressing, Gene Expression

Journal: Scientific Reports

Article Title: Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma

doi: 10.1038/s41598-025-90121-0

Figure Lengend Snippet: Pan-cancer analysis of the relationship between ADAM12 expression and immune cell infiltration. ( A ) Immune cell infiltration across pan-cancer types analyzed using QUANTISEQ algorithms. *p < 0.05, **p < 0.01, ***p < 0.001. ( B ) The heat map in the schematic represents the correlation analysis of the immune score in TCGA-GBMLGG. ( C ) Spearman correlation analysis of ADAM12 expression with immune infltrating cells in glioma. ( D ) Distribution of QUANTISEQ immune scores in high and low ADAM12 expression groups of glioma. The horizontal axis represents immune cell types, while the vertical axis indicates the distribution of immune scores across different groups. G1: high group of ADAM12 in glioma. G2: low group of ADAM12 in glioma.

Article Snippet: In line with these findings, data from the Human Protein Atlas (HPA) also confirmed elevated ADAM12 expression in brain and kidney cancers (Fig. C).

Techniques: Expressing

Journal: Scientific Reports

Article Title: Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma

doi: 10.1038/s41598-025-90121-0

Figure Lengend Snippet: Single-cell RNA sequencing analysis of the functional state of ADAM12 in Pan-cancer and its expression in normal tissues. ( A ) Single-cell analysis illustrating the functional state of ADAM12 in Pan-cancer. ( B ) CancerSEA analysis demonstrated that ADAM12 positively correlated with differentiation, angiogenesis, and proliferation in glioma. Single-cell sequencing analysis showed the expression of ADAM12 in normal tissues from Tabula Muris DataBase, including the Brain ( C ) and Kidney ( D ).

Article Snippet: In line with these findings, data from the Human Protein Atlas (HPA) also confirmed elevated ADAM12 expression in brain and kidney cancers (Fig. C).

Techniques: RNA Sequencing, Functional Assay, Expressing, Single-cell Analysis, Sequencing

Journal: Scientific Reports

Article Title: Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma

doi: 10.1038/s41598-025-90121-0

Figure Lengend Snippet: Single-cell RNA sequencing analysis of the expression of ADAM12 in tumors. ( A ) ADAM12 was mainly expressed in stromal cells and glioma cells in the UCSC Cell Browser. ( B ) ADAM12 was mainly expressed in Malignant cells in Glioma_GSE148842 in TISCH DataBase. ( C )ADAM12 was mainly expressed in Mast cells in LIHC_GSE140228 in the TISCH Database. ( D )ADAM12 was mainly expressed in Fibroblast cells in OV_GSE147082 in the TISCH Database. ( E ) ADAM12 was mainly expressed in Malignant cells and Endothelial cells in UVM_GSE138433 in the TISCH Database.

Article Snippet: In line with these findings, data from the Human Protein Atlas (HPA) also confirmed elevated ADAM12 expression in brain and kidney cancers (Fig. C).

Techniques: RNA Sequencing, Expressing

Journal: Scientific Reports

Article Title: Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma

doi: 10.1038/s41598-025-90121-0

Figure Lengend Snippet: Enrichment function for ADAM12 in glioma. ( A ) Heatmaps displaying the expression of the top 50 genes positively and negatively correlated with ADAM12. ( B ) Volcano plot of DEGs between high and low ADAM12 expressions. ( C ) GO analysis of the DEGs based on the ADAM12 expression in glioma. ( D ) KEGG analysis of the DEGs based on the ADAM12 expression in glioma. ( E ) The GSEA analysis results of the DEGs based on the ADAM12 expression in glioma.

Article Snippet: In line with these findings, data from the Human Protein Atlas (HPA) also confirmed elevated ADAM12 expression in brain and kidney cancers (Fig. C).

Techniques: Expressing

Journal: Scientific Reports

Article Title: Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma

doi: 10.1038/s41598-025-90121-0

Figure Lengend Snippet: ADAM12 promotes the malignant progression of glioma cells. ( A ) Protein levels of ADAM12 in six pairs of glioma tissues (T) and adjacent non-tumor tissues (N).Full-length original Western blots are presented in Supplementary Fig S5A. ( B , C ) Validation of siRNA interference efficiency in knockdown of ADAM12 expression in U87 and U251 cells by RT-qPCR and Weston blotting.Full-length original Western blots are presented in Supplementary Fig S5B. ( D ) CCK8 assay to detect the proliferative capacity of transfected U87 and U251. ( E , F ) Wound healing assay for negative control and ADAM12 knockout groups. ( G ) Colony formation assay for negative control and ADAM12 knockout groups. ( H , I ) Transwell assay images of migration and invasion in the negative control and ADAM12 knockout groups. *p < 0.05; **p < 0.01; ***p < 0.001.

Article Snippet: In line with these findings, data from the Human Protein Atlas (HPA) also confirmed elevated ADAM12 expression in brain and kidney cancers (Fig. C).

Techniques: Western Blot, Biomarker Discovery, Knockdown, Expressing, Quantitative RT-PCR, CCK-8 Assay, Transfection, Wound Healing Assay, Negative Control, Knock-Out, Colony Assay, Transwell Assay, Migration

Journal: iScience

Article Title: Perturbation of EPHA2 and EFNA1 trans binding amplifies inflammatory response in airway epithelial cells

doi: 10.1016/j.isci.2025.111872

Figure Lengend Snippet: Q-RT-PCR primer list

Article Snippet: Silencer® Select siRNA Human ADAM12 , Thermo Fisher Scientific , Cat# s15575.

Techniques:

Journal: iScience

Article Title: Perturbation of EPHA2 and EFNA1 trans binding amplifies inflammatory response in airway epithelial cells

doi: 10.1016/j.isci.2025.111872

Figure Lengend Snippet:

Article Snippet: Silencer® Select siRNA Human ADAM12 , Thermo Fisher Scientific , Cat# s15575.

Techniques: Virus, Recombinant, Enzyme-linked Immunosorbent Assay, DNA Sequencing, Plasmid Preparation, Software